Laboratory Company Top Insiders
LH Stock | USD 199.45 0.52 0.26% |
Laboratory's insiders are aggressively selling. The analysis of insiders' sentiment of trading Laboratory of stock suggests that almost all insiders are panicking at this time. Laboratory employs about 57 K people. The company is managed by 49 executives with a total tenure of roughly 304 years, averaging almost 6.0 years of service per executive, having 1162.24 employees per reported executive.
Deborah Tanner CEO CEO - Covance Drug Development (Covance) |
Gary Huff CEO CEO, LabCorp Diagnostics |
Laboratory's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-04-01 | Mark S Schroeder | Disposed 6477 @ 217.29 | View | ||
2024-03-28 | Der Vaart Sandra D Van | Disposed 3553 @ 216.74 | View | ||
2024-03-07 | Mark S Schroeder | Disposed 5048 @ 218.45 | View | ||
2024-02-21 | Jonathan P Divincenzo | Disposed 500 @ 215.49 | View | ||
2024-02-13 | Der Vaart Sandra D Van | Disposed 237 @ 226.45 | View | ||
2024-02-08 | Der Vaart Sandra D Van | Disposed 259 @ 222.06 | View | ||
2023-11-16 | Peter J Wilkinson | Disposed 1384 @ 210.71 | View | ||
2023-08-22 | Dan Sullivan | Disposed @ 214.78 | |||
2023-08-08 | Kerrii B Anderson | Disposed 5000 @ 211.57 | View | ||
2023-06-29 | Der Vaart Sandra D Van | Disposed 212 @ 240 | View | ||
2023-05-19 | Paul R Kirchgraber | Disposed 4300 @ 216.91 | View | ||
2023-05-18 | Mark S Schroeder | Disposed 1500 @ 216.77 | View |
Monitoring Laboratory's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Laboratory |
Laboratory's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Laboratory's future performance. Based on our forecasts, it is anticipated that Laboratory will maintain a workforce of under 56950 employees by May 2024.Laboratory's latest congressional trading
Congressional trading in companies like Laboratory, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Laboratory by those in governmental positions are based on the same information available to the general public.
2023-08-22 | Senator Daniel S Sullivan | Acquired Under $15K | Verify | ||
2020-12-16 | Representative Susie Lee | Disposed Under $15K | Verify | ||
2020-03-18 | Representative Gilbert Cisneros | Disposed Under $15K | Verify | ||
2020-01-09 | Representative Mike Gallagher | Disposed Under $15K | Verify | ||
2019-04-26 | Senator James M Inhofe | Acquired $50K to $100K | Verify | ||
2019-04-26 | Senator James M. Inhofe | Acquired $50K to $100K | Verify | ||
2018-09-05 | Representative Bradley S. Schneider | Disposed $250K to $500K | Verify |
Laboratory Management Team Effectiveness
The company has Return on Asset (ROA) of 0.0377 % which means that for every $100 of assets, it generated a profit of $0.0377. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.0423 %, which means that it produced $0.0423 on every 100 dollars invested by current stockholders. Laboratory's management efficiency ratios could be used to measure how well Laboratory manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to 0.05. The current Return On Capital Employed is estimated to decrease to 0.08. As of now, Laboratory's Total Current Assets are increasing as compared to previous years. The Laboratory's current Other Assets is estimated to increase to about 531.7 M, while Non Currrent Assets Other are projected to decrease to under 270.8 M.The Laboratory's current Common Stock Shares Outstanding is estimated to increase to about 96 M. The Laboratory's current Net Income Applicable To Common Shares is estimated to increase to about 1.5 B
Laboratory Workforce Comparison
Laboratory of is rated third overall in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 271,859. Laboratory totals roughly 56,950 in number of employees claiming about 21% of equities under Health Care industry.
Laboratory Profit Margins
The company has Net Profit Margin (PM) of 0.03 %, which suggests that even a small decline in it sales will erase profits and may result in a net loss, or a negative profit margin. This is way below average. Likewise, it shows Net Operating Margin (NOM) of 0.07 %, which signifies that for every $100 of sales, it has a net operating income of $0.07.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.42 | 0.2586 |
|
| |||||
Net Profit Margin | 0.0674 | 0.0344 |
|
| |||||
Operating Profit Margin | 0.18 | 0.0924 |
|
| |||||
Pretax Profit Margin | 0.0444 | 0.0468 |
|
| |||||
Return On Assets | 0.0237 | 0.025 |
|
| |||||
Return On Equity | 0.0504 | 0.0531 |
|
|
Laboratory Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Laboratory insiders, such as employees or executives, is commonly permitted as long as it does not rely on Laboratory's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Laboratory insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-06-01 | 0.3333 | 2 | 6 | 10,434 | 24,976 |
2024-03-01 | 0.8056 | 87 | 108 | 303,211 | 297,981 |
2023-12-01 | 0.5 | 2 | 4 | 436.00 | 1,839 |
2023-09-01 | 0.3333 | 1 | 3 | 56.00 | 5,073 |
2023-06-01 | 2.0 | 22 | 11 | 158,353 | 15,832 |
2023-03-01 | 0.9111 | 82 | 90 | 225,878 | 89,157 |
2022-12-01 | 0.7273 | 8 | 11 | 38,739 | 30,103 |
2022-09-01 | 0.2941 | 5 | 17 | 32,917 | 104,216 |
2022-03-01 | 0.9186 | 79 | 86 | 156,968 | 58,112 |
2021-12-01 | 0.2941 | 5 | 17 | 17,058 | 26,724 |
2021-09-01 | 0.5 | 2 | 4 | 4,550 | 9,065 |
2021-06-01 | 0.4286 | 3 | 7 | 8,110 | 18,162 |
2021-03-01 | 0.9 | 72 | 80 | 135,493 | 47,163 |
2020-12-01 | 0.4286 | 6 | 14 | 17,229 | 27,598 |
2020-09-01 | 0.5 | 3 | 6 | 2,420 | 5,443 |
2020-06-01 | 0.2 | 1 | 5 | 1,010 | 33,504 |
2020-03-01 | 0.9605 | 73 | 76 | 293,460 | 118,837 |
2019-12-01 | 1.0 | 9 | 9 | 147,524 | 36,645 |
2019-09-01 | 0.2222 | 2 | 9 | 5,066 | 26,216 |
2019-06-01 | 0.5263 | 10 | 19 | 148,322 | 92,882 |
2019-03-01 | 0.8906 | 57 | 64 | 197,097 | 73,462 |
2018-12-01 | 0.5 | 2 | 4 | 6,874 | 8,360 |
2018-09-01 | 0.25 | 1 | 4 | 153.00 | 2,306 |
2018-06-01 | 0.25 | 5 | 20 | 128,553 | 253,615 |
2018-03-01 | 0.8947 | 68 | 76 | 341,205 | 239,230 |
2017-09-01 | 0.381 | 8 | 21 | 213,123 | 439,693 |
2017-06-01 | 0.8 | 4 | 5 | 17,432 | 11,573 |
2017-03-01 | 0.8312 | 64 | 77 | 350,653 | 176,413 |
2016-12-01 | 1.0 | 2 | 2 | 49,901 | 31,601 |
2016-09-01 | 0.2 | 1 | 5 | 992.00 | 11,161 |
2016-06-01 | 0.3 | 3 | 10 | 200,450 | 411,918 |
2016-03-01 | 0.7179 | 56 | 78 | 312,339 | 252,898 |
2015-12-01 | 0.25 | 2 | 8 | 3,146 | 6,006 |
2015-09-01 | 0.375 | 3 | 8 | 119,990 | 229,576 |
2015-06-01 | 0.2632 | 5 | 19 | 57,060 | 113,853 |
2015-03-01 | 0.6667 | 44 | 66 | 144,102 | 159,333 |
2014-12-01 | 0.3333 | 1 | 3 | 624.00 | 1,718 |
2014-09-01 | 0.3 | 3 | 10 | 195,700 | 393,400 |
2014-06-01 | 1.1053 | 21 | 19 | 127,379 | 191,432 |
2014-03-01 | 0.4138 | 12 | 29 | 125,329 | 145,306 |
2013-12-01 | 0.6 | 6 | 10 | 100,024 | 188,800 |
2013-09-01 | 0.5 | 4 | 8 | 100,000 | 132,429 |
2013-06-01 | 0.6296 | 17 | 27 | 320,270 | 584,451 |
2013-03-01 | 0.4706 | 8 | 17 | 105,453 | 41,638 |
2012-09-01 | 0.625 | 5 | 8 | 149,294 | 254,830 |
2012-06-01 | 3.0 | 9 | 3 | 285,700 | 5,687 |
2012-03-01 | 0.5 | 15 | 30 | 260,005 | 274,061 |
2011-12-01 | 0.5 | 1 | 2 | 20,000 | 40,000 |
2011-09-01 | 0.6667 | 2 | 3 | 1,353 | 2,170 |
2011-06-01 | 1.3333 | 12 | 9 | 22,792 | 22,909 |
2011-03-01 | 0.6207 | 18 | 29 | 438,936 | 102,157 |
2010-12-01 | 0.375 | 3 | 8 | 65,366 | 132,494 |
2010-09-01 | 0.75 | 3 | 4 | 14,096 | 4,716 |
2010-06-01 | 1.4286 | 10 | 7 | 31,000 | 36,686 |
2010-03-01 | 0.65 | 13 | 20 | 487,600 | 78,161 |
2009-12-01 | 0.2 | 1 | 5 | 4,116 | 22,080 |
2009-09-01 | 1.0 | 2 | 2 | 50,700 | 854.00 |
2009-06-01 | 2.0 | 8 | 4 | 19,200 | 33,707 |
2009-03-01 | 0.5217 | 12 | 23 | 608,000 | 25,320 |
2008-06-01 | 0.371 | 23 | 62 | 568,776 | 12,548 |
2008-03-01 | 0.0755 | 33 | 437 | 354,093 | 385,564 |
2007-12-01 | 0.7143 | 15 | 21 | 35,260 | 72,386 |
2007-09-01 | 1.5455 | 17 | 11 | 95,452 | 95,856 |
2007-06-01 | 0.3218 | 28 | 87 | 39,074 | 82,599 |
2007-03-01 | 0.3179 | 48 | 151 | 631,190 | 228,173 |
2006-12-01 | 1.3636 | 15 | 11 | 14,288 | 28,000 |
2006-09-01 | 1.0556 | 19 | 18 | 27,060 | 53,993 |
2006-06-01 | 0.5962 | 31 | 52 | 90,974 | 170,945 |
2006-03-01 | 0.1429 | 57 | 399 | 976,027 | 1,306,343 |
2005-12-01 | 1.6667 | 15 | 9 | 13,996 | 29,233 |
2005-09-01 | 2.25 | 18 | 8 | 61,125 | 121,546 |
2005-06-01 | 0.7273 | 32 | 44 | 101,455 | 174,097 |
2005-03-01 | 0.1489 | 35 | 235 | 505,023 | 713,208 |
2004-12-01 | 0.5972 | 43 | 72 | 546,198 | 1,089,771 |
2004-09-01 | 9.0 | 18 | 2 | 3,303 | 286.00 |
2004-06-01 | 0.6735 | 33 | 49 | 143,456 | 206,000 |
2004-03-01 | 0.1051 | 29 | 276 | 691,714 | 812,942 |
2003-12-01 | 0.6154 | 16 | 26 | 64,604 | 70,000 |
2003-09-01 | 0.6 | 12 | 20 | 19,700 | 62,962 |
Laboratory Notable Stakeholders
A Laboratory stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Laboratory often face trade-offs trying to please all of them. Laboratory's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Laboratory's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Deborah Tanner | CEO - Covance Drug Development (Covance) | Profile | |
Gary Huff | CEO, LabCorp Diagnostics | Profile | |
John Ratliff | Chief Executive Officer - Covance Drug Development | Profile | |
Paul Kirchgraber | Executive Vice President and Chief Executive Officer - Covance Drug Development | Profile | |
James Boyle | Executive VP and CEO of Labcorp Diagnostics | Profile | |
David King | Chairman of the Board, President, Chief Executive Officer | Profile | |
Adam Schechter | Chairman of the Board, President, Chief Executive Officer | Profile | |
William Klitgaard | President- Enlighten Health | Profile | |
Stephen Anderson | Vice President Investor Relations | Profile | |
JD MD | President EVP | Profile | |
Peter Wilkinson | Senior Vice President, Chief Accounting Officer | Profile | |
Lisa Uthgenannt | Chief Human Resource Officer, Senior Vice President | Profile | |
Brian Caveney | Executive Vice President, President, Diagnostics and Chief Medical Officer | Profile | |
Mark Brecher | Senior Vice President Chief Medical Officer | Profile | |
Samuel Eberts | Senior Vice President Chief Compliance Officer, Secretary, Chief Legal Officer | Profile | |
Sandra Vaart | Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | Profile | |
Glenn Eisenberg | Chief Financial Officer, Executive Vice President | Profile | |
Lance Berberian | Executive Vice President, Chief Technology Officer, Chief Information Officer | Profile | |
Scott Frommer | Vice President - Investor Relations | Profile | |
Edward Dodson | Chief Accounting Officer and Sr. VP | Profile | |
Sanders Williams | Independent Director | Profile | |
JeanLuc Belingard | Independent Director | Profile | |
Peter Neupert | Lead Independent Director | Profile | |
Robert Williams | Independent Director | Profile | |
Garheng Kong | Independent Director | Profile | |
Gary Gilliland | Independent Director | Profile | |
Robert Mittelstaedt | Lead Independent Director | Profile | |
Kerrii Anderson | Independent Director | Profile | |
Richelle Parham | Independent Director | Profile | |
Jeffrey Davis | Independent Director | Profile | |
Deborah SesokPizzini | SVP Officer | Profile | |
Paul Surdez | IR Contact Officer | Profile | |
Amy Summy | Executive Vice President Chief Marketing Officer | Profile | |
Mark Schroeder | Executive Vice President and Presidentident of Diagnostics Laboratory Operations and Global Supply Chain | Profile | |
Robert Pringle | Senior Treasurer | Profile | |
D Gilliland | Independent Director | Profile | |
Clarissa Willett | IR Contact Officer | Profile | |
Megan MPH | Executive Officer | Profile | |
Chas Cook | VP Relations | Profile | |
Anita Graham | Executive Officer | Profile | |
Judith Seltz | Chief Human Resource Officer, Executive Vice President | Profile | |
Michelle Abelson | Laboratory Operations | Profile | |
Jonathan DiVincenzo | Executive International | Profile | |
Paul MD | Ex Devel | Profile | |
Marcia Eisenberg | Chief VP | Profile | |
John Treadwell | Vice Initiatives | Profile | |
Kathryn Wengel | Independent Director | Profile | |
Christin ODonnell | Vice Relations | Profile | |
MPH MD | Pres VP | Profile |
About Laboratory Management Performance
The success or failure of an entity such as Laboratory often depends on how effective the management is. Laboratory management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Laboratory management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Laboratory management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.06 | 0.05 | |
Return On Capital Employed | 0.08 | 0.08 | |
Return On Assets | 0.02 | 0.02 | |
Return On Equity | 0.05 | 0.05 |
The data published in Laboratory's official financial statements usually reflect Laboratory's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Laboratory. For example, before you start analyzing numbers published by Laboratory accountants, it's critical to develop an understanding of what Laboratory's liquidity, profitability, and earnings quality are in the context of the Health Care Providers & Services space in which it operates.
Please note, the presentation of Laboratory's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Laboratory's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Laboratory's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Laboratory of. Please utilize our Beneish M Score to check the likelihood of Laboratory's management manipulating its earnings.
Laboratory Workforce Analysis
Traditionally, organizations such as Laboratory use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Laboratory within its industry.Laboratory Manpower Efficiency
Return on Laboratory Manpower
Revenue Per Employee | 213.5K | |
Revenue Per Executive | 248.2M | |
Net Income Per Employee | 6.7K | |
Net Income Per Executive | 7.7M | |
Working Capital Per Employee | 9.5K | |
Working Capital Per Executive | 11M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory of. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Laboratory information on this page should be used as a complementary analysis to other Laboratory's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Laboratory Stock analysis
When running Laboratory's price analysis, check to measure Laboratory's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Laboratory is operating at the current time. Most of Laboratory's value examination focuses on studying past and present price action to predict the probability of Laboratory's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Laboratory's price. Additionally, you may evaluate how the addition of Laboratory to your portfolios can decrease your overall portfolio volatility.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
CEOs Directory Screen CEOs from public companies around the world | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Laboratory's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Laboratory. If investors know Laboratory will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Laboratory listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.46) | Dividend Share 2.88 | Earnings Share 4.32 | Revenue Per Share 139.628 | Quarterly Revenue Growth 0.035 |
The market value of Laboratory is measured differently than its book value, which is the value of Laboratory that is recorded on the company's balance sheet. Investors also form their own opinion of Laboratory's value that differs from its market value or its book value, called intrinsic value, which is Laboratory's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Laboratory's market value can be influenced by many factors that don't directly affect Laboratory's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Laboratory's value and its price as these two are different measures arrived at by different means. Investors typically determine if Laboratory is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Laboratory's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.